Amarantus BioScience, Inc. (AMBS) Licenses Memory Dx LymPro Alzheimer’s Diagnostic Test
Amarantus BioScience has licensed the LymPro Alzheimer’s Disease Diagnostic Blood Test from Memory Dx LLC (MDx), growing Amarantus’ existing diagnostic pipeline and positioning the company to participate in related future opportunities. LymPro, designed to diagnose Alzheimer’s in its mild to moderate stage, has completed two phase 1 clinical studies and is ready to move into a phase 2 validation study. If successful, Amarantus anticipates that LymPro can begin generating revenue as a laboratory-developed test within 18 months of study initiation, through commercial sales and sales to companies performing Alzheimer’s disease clinical research. “We believe LymPro has significant clinical and commercial…